Alcoholic liver disease diagnosis is suggested by an established history of habitual alcohol intake of sufficient length and intensity.
Toxic daily threshold of alcohol consumption is 40-80 g for males and 20-40 g for females for 10-12 years.
Signs of alcohol abuse and hepatic injury include malnutrition and muscle wasting, cutaneous telangiectasia, palmar erythema, finger clubbing, Dupuytren's contracture, peripheral neuropathy, parotid gland enlargement and signs of gynecomastia and hypogonadism may also be present.
Early liver transplantation (LT) should be considered in selected patients with severe alcoholic hepatitis (SAH) as it significantly improves survival with a low impact on the donor pool, according to recent data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong.
Dual therapy with corticosteroid and pentoxifylline is as good as corticosteroid monotherapy at reducing mortality risk in severe alcoholic hepatitis, but shows superiority in terms of reducing hepatorenal syndrome or acute kidney injury incidence and infection risk, according to a meta-analysis of 25 studies.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Gastroenterology - Malaysia digital copy today!
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.